Anderson Cancer Center (MDACC) by Dr. Beth Mittendorf. If a patient submits a prior HLA-2/A3/A24/A26 positive typing report from an outside CLIA certified lab, this will be accepted for screening. Only HLA-A2, A3, A24, or A26 positive patients will be enrolled in the trial. Those patients who are not HLA-A2, A3, A24, or A26 positive will be excluded. Patients will be counseled prior to obtaining consent that lack of HLA-A2, A3, A24, or A26 positivity will result in exclusion. 4.1.2 Inclusion Criteria Patients will be included in the study based on the following criteria: • Women 18 years or older • Node-positive breast cancer (AJCC N1, N2, or N3) • Node-negative breast cancer if negative for both estrogen (ER) and progesterone (PR) receptors and have received chemotherapy as standard of care • Clinically cancer-free (no evidence of disease) after standard of care therapy (surgery, chemotherapy, radiation therapy as directed by NCCN guidelines). Hormonal therapy will continue per standard of care.